Strategic targeting of the PI3K-NFκB axis in cisplatin-resistant NSCLC

Cancer Biology and Therapy

Volumn 15, Issue 10, 2014, Pages 1367-1377

  Heavey, Susan ^a   Godwin, Peter ^a   Baird, Anne Marie ^b   Barr, Martin P ^a   Umezawa, Kazuo ^c   Cuffe, Sinéad ^a   Finn, Stephen P ^a   O'Byrne, Kenneth J ^b   Gately, Kathy ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^c AICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

A549; Chemoresistance; Chemotherapy; DHMEQ; Drug resistance; GDC 0980; H460; Lung cancer; Non small cell lung cancer

Indexed keywords

APITOLISIB; CISPLATIN; DEHYDROXYMETHYLEPOXYQUINOMICIN; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; 1-(4-((2-(2-AMINOPYRIMIDIN-5-YL)-7-METHYL-4-MORPHOLINOTHIENO(3,2-D)PYRIMIDIN-6-YL)METHYL)PIPERAZIN-1-YL)-2-HYDROXYPROPAN-1-ONE; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; CYCLOHEXANONE DERIVATIVE; FUSED HETEROCYCLIC RINGS; PYRIMIDINE DERIVATIVE; TRANSCRIPTOME;

AMPLICON; ARTICLE; BRDU ASSAY; CANCER RESISTANCE; CELL PROLIFERATION; CELL VIABILITY; CELL VIABILITY ASSAY; CONTROLLED STUDY; DENSITOMETRY; DNA SEQUENCE; DOWN REGULATION; DRUG EXPOSURE; EXON; GENE OVEREXPRESSION; IMMUNOFLUORESCENCE; LONG TERM EXPOSURE; LUNG CANCER CELL LINE; MULTIPARAMETER VIABILITY ASSAY; NON SMALL CELL LUNG CANCER; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING; WILD TYPE; ANTAGONISTS AND INHIBITORS; DRUG RESISTANCE; HUMAN; LUNG TUMOR; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BENZAMIDES; BICYCLO COMPOUNDS, HETEROCYCLIC; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CISPLATIN; CYCLOHEXANONES; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; NF-KAPPA B; PHOSPHATIDYLINOSITOL 3-KINASES; PYRIMIDINES; TRANSCRIPTOME;

EID: 84908461196     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.29841     Document Type: Article

References (33)

1. Parkin DM Global cancer statistics in the year 2000. Lancet Oncol 2001; 2: 533-43; PMID: 11905707; http://dx.doi.org/10.1016/S1470-2045(01)00486-7
2. Pfannschmidt J, Muley T, Bülzebruck H, Hoffmann H, Dienemann H. Prognostic assessment after surgical resection for non-small cell lung cancer: experiences in 2083 patients. Lung Cancer 2007; 55: 371-7; PMID: 17123661; http://dx.doi.org/10.1016/j.lungcan.2006.10.017
3. Godwin P, Baird AM, Heavey S, Barr MP, O'Byrne KJ, Gately K. Targeting nuclear factor-kappa B to overcome resistance to chemotherapy. Front Oncol 2013; 3: 120; PMID: 23720710; http://dx.doi.org/10.3389/fonc.2013.00120
4. Godwin AK, Meister A, O'Dwyer PJ, Huang CS, Hamilton TC, Anderson ME. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci U S A 1992; 89: 3070-4; PMID: 1348364; http://dx.doi.org/10.1073/pnas.89.7.3070
5. Yang H, Kong W, He L, Zhao JJ, O'Donnell JD, Wang J, Wenham RM, Coppola D, Kruk PA, Nicosia SV, et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 2008; 68: 425-33; PMID: 18199536; http://dx.doi.org/10.1158/0008-5472.CAN-07-2488
6. Whitman M, Kaplan DR, Schaffhausen B, Cantley L, Roberts TM. Association of phospha-tidylinositol kinase activity with polyoma middle-T competent for transformation. Nature 1985; 315: 239-42; PMID: 2987699; http://dx.doi.org/10.1038/315239a0
7. Currie RA, Walker KS, Gray A, Deak M, Casamayor A, Downes CP, Cohen P, Alessi DR, Lucocq J. Role of phosphatidylinositol 3,4,5-trisphosphate in regulating the activity and localization of 3-phos-phoinositide-dependent protein kinase-1. Biochem J 1999; 337: 575-83; PMID: 9895304; http://dx.doi.org/10.1042/0264-6021:3370575
8. Duronio V. The life of a cell: apoptosis regulation by the PI3K/PKB pathway. Biochem J 2008; 415: 333-44; PMID: 18842113; http://dx.doi.org/10.1042/BJ20081056
9. Peng DJ, Wang J, Zhou JY, Wu GS. Role of the Akt/mTOR survival pathway in cisplatin resistance in ovarian cancer cells. Biochem Biophys Res Commun 2010; 394: 600-5; PMID: 20214883; http://dx.doi.org/10.1016/j.bbrc.2010.03.029
10. Zhang B, Zhang K, Liu Z, Hao F, Wang M, Li X, Yin Z, Liang H. Secreted clusterin gene silencing enhances chemosensitivity of a549 cells to cisplatin through AKT and ERK1/2 pathways in vitro. Cell Physiol Biochem 2014; 33: 1162-75; PMID: 24751980; http://dx.doi.org/10.1159/000358685
11. Wang M, Liu ZM, Li XC, Yao YT, Yin ZX. Activation of ERK1/2 and Akt is associated with cisplatin resistance in human lung cancer cells. J Chemother 2013; 25: 162-9; PMID: 23783141; http://dx.doi.org/10.1179/1973947812Y.0000000056
12. Lee MW, Kim DS, Min NY, Kim HT. Akt1 inhibition by RNA interference sensitizes human non-small cell lung cancer cells to cisplatin. Int J Cancer 2008; 122: 2380-4; PMID: 18224693; http://dx.doi.org/10.1002/ijc.23371
13. Belyanskaya LL, Hopkins-Donaldson S, Kurtz S. Simões-Wüst AP, Yousefi S, Simon HU, Stahel R, Zangemeister-Wittke U. Cisplatin activates Akt in small cell lung cancer cells and attenuates apoptosis by survivin upregulation. Int J Cancer 2005; 117: 755-63; PMID: 15981204; http://dx.doi.org/10.1002/ijc.21242
14. Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol 2010; 28: 1075-83; PMID: 20085938; http://dx.doi.org/10.1200/JCO.2009.25.3641
15. Heavey S, O'Byrne KJ, Gately K. Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC. Cancer Treat Rev 2014; 40: 445-56; PMID: 24055012; http://dx.doi.org/10.1016/j.ctrv.2013.08.006
16. Genentech. Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy. ClinicalTrialsgov [Internet]. Available from: http://clinicaltri-als.gov/ct2/show/NCT01437566?term=GDC-0980&rank=6: Accessed 28/04/13, Identifier: NCT01437566; 2011.
17. Wallin JJ, Edgar KA, Guan J, Berry M, Prior W W, Lee L, Lesnick JD, Lewis C, Nonomiya J, Pang J, et al. GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway. Mol Cancer Ther 2011; 10: 2426-36; PMID: 21998291; http://dx.doi.org/10.1158/1535-7163.MCT-11-0446
18. Jacobs MD, Harrison SC. Structure of an IkappaBalpha/NF-kappaB complex. Cell 1998; 95: 749-58; PMID: 9865693; http://dx.doi.org/10.1016/S0092-8674(00)81698-0
19. Régnier CH, Song HY, Gao X, Goeddel DV, Cao Z, Rothe M. Identification and characterization of an IkappaB kinase. Cell 1997; 90: 373-83; PMID: 9244310; http://dx.doi.org/10.1016/S0092-8674(00)80344-X
20. Arenzana-Seisdedos F, Turpin P, Rodriguez M, Thomas D, Hay RT, Virelizier JL, Dargemont C. Nuclear localization of I kappa B alpha promotes active transport of NF-kappa B from the nucleus to the cytoplasm. J Cell Sci 1997; 110: 369-78; PMID: 9057089
21. Emmerich F, Meiser M, Hummel M, Demel G, Foss HD, Jundt F, Mathas S, Krappmann D, Scheidereit C, Stein H, et al. Overexpression of I kappa B alpha without inhibition of NF-kappaB activity and mutations in the I kappa B alpha gene in Reed-Sternberg cells. Blood 1999; 94: 3129-34; PMID: 10556199
22. Cabannes E, Khan G, Aillet F, Jarrett RF, Hay RT. Mutations in the IkBa gene in Hodgkin's disease suggest a tumour suppressor role for IkappaBalpha. Oncogene 1999; 18: 3063-70; PMID: 10340377; http://dx.doi.org/10.1038/sj.onc.1202893
23. Ariga A, Namekawa J, Matsumoto N, Inoue J, Umezawa K. Inhibition of tumor necrosis factor-alpha-induced nuclear translocation and activation of NF-kappa B by dehydroxymethylepoxyquinomicin. J Biol Chem 2002; 277: 24625-30; PMID: 11983688; http://dx.doi.org/10.1074/jbc.M112063200
24. Kikuchi E, Horiguchi Y, Nakashima J, Kuroda K, Oya M, Ohigashi T, Takahashi N, Shima Y, Umezawa K, Murai M. Suppression of hormone-refractory prostate cancer by a novel nuclear factor kappaB inhibitor in nude mice. Cancer Res 2003; 63: 107-10; PMID: 12517785
25. Starenki DV, Namba H, Saenko VA, Ohtsuru A, Maeda S, Umezawa K, Yamashita S. Induction of thyroid cancer cell apoptosis by a novel nuclear factor kappaB inhibitor, dehydroxymethylepoxy-quinomicin. Clin Cancer Res 2004; 10: 6821-9; PMID: 15501958; http://dx.doi.org/10.1158/1078-0432.CCR-04-0463
26. Matsumoto G, Namekawa J, Muta M, Nakamura T, Bando H, Tohyama K, Toi M, Umezawa K. Targeting of nuclear factor kappaB Pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo. Clin Cancer Res 2005; 11: 1287-93; PMID: 15709200
27. Watanabe M, Dewan MZ, Okamura T, Sasaki M, Itoh K, Higashihara M, Mizoguchi H, Honda M, Sata T, Watanabe T, et al. A novel NF-kappaB inhibitor DHMEQ selectively targets constitutive NF-kappaB activity and induces apoptosis of multiple myeloma cells in vitro and in vivo. Int J Cancer 2005; 114: 32-8; PMID: 15523684; http://dx.doi.org/10.1002/ijc.20688
28. Katsman A, Umezawa K, Bonavida B. Reversal of resistance to cytotoxic cancer therapies: DHMEQ as a chemo-sensitizing and immuno-sensitizing agent. Drug Resist Updat 2007; 10: 1-12; PMID: 17306602; http://dx.doi.org/10.1016/j.drup.2007.01.002
29. Katsman A, Umezawa K, Bonavida B. Chemosensitization and immunosensitization of resistant cancer cells to apoptosis and inhibition of metastasis by the specific NF-kappaB inhibitor DHMEQ. Curr Pharm Des 2009; 15: 792-808; PMID: 19275643; http://dx.doi.org/10.2174/138161209787582156
30. Castro-Gamero AM, Borges KS. da Silva Silveira V, Lira RC, de Paula Gomes Queiroz R, Valera FC, Scrideli CA, Umezawa K, Tone LG. Inhibition of nuclear factor-κB by dehydroxymethylepoxyquin-omicin induces schedule-dependent chemosensitiv-ity to anticancer drugs and enhances chemoinduced apoptosis in osteosarcoma cells. Anticancer Drugs 2012; 23: 638-50; PMID: 22382389; http://dx.doi.org/10.1097/CAD.0b013e328350e835
31. Umezawa K. Possible role of peritoneal NF-κB in peripheral inflammation and cancer: lessons from the inhibitor DHMEQ. Biomed Pharmacother 2011; 65: 252-9; PMID: 21723080; http://dx.doi.org/10.1016/j.biopha.2011.02.003
32. Lake A, Shield LA, Cordano P, Chui DT, Osborne J, Crae S, Wilson KS, Tosi S, Knight SJ, Gesk S, et al. Mutations of NFKBIA, encoding IkappaB alpha, are a recurrent finding in classical Hodgkin lymphoma but are not a unifying feature of non-EBV-associated cases. Int J Cancer 2009; 125: 1334-42; PMID: 19507254; http://dx.doi.org/10.1002/ijc.24502
33. Barr MP, Gray SG, Hoffmann AC, Hilger RA, Thomale J, O'Flaherty JD, Fennell DA, Richard D, O'Leary JJ. O'Byrne KJ. Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature. PLoS One 2013; 8: e54193; PMID: 23349823; http://dx.doi.org/10.1371/journal.pone.0054193